Jichuan Pharmaceutical: Chai Ge Antipyretic Oral Liquid Registration Application Accepted

Jichuan Pharmaceutical Co., Ltd. announced that its wholly owned subsidiary, Jichuan Limited, has received the “Acceptance Notice” issued by the National Medical Products Administration for the application to register for market listing of “Chai Ge Fever-Reducing Oral Liquid.” This medicine is a Class 1.1 traditional Chinese medicine, mainly used to treat symptoms such as fever and headache caused by wind-heat type common colds. As of now, the project has accumulated investment of 59.1456 million yuan. According to publicly available information, there is currently no information in China on drug listings or registration application submissions that match its prescription. This acceptance indicates that the domestic drug registration work for the product has entered the review stage, and the future market has room for development.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin